Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Faisal Shahjehan MD
Assistant Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:
Froedtert Hospital
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
2006 - 2012 Bachelor of Medicine, Bachelor of Surgery (M.B.B.S), University of Health Sciences, Lahore, Pakistan

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
07/2017 - 11/2018 Research Trainee, Hematology & Oncology, Mayo Clinic, FL
07/2019 - 06/2022 Internal Medicine Resident, Conemaugh Memorial Medical Center, Johnstown, PA
2021 - 2022 Chief Resident, Conemaugh Memorial Medical Center, Johnstown, PA

FACULTY APPOINTMENTS:
04/2013 - 03/2016 General Practitioner, Wapda Hospital, Pakistan
10/2022 - 06/2024 Hospitalist, Iberia Medical Center, New Iberia, LA
06/01/2024 - Present Assistant Professor/Hospitalist, Medicine, Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53236

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
04/2012 - 03/2013 House Officer, POF Hospital, Pakistan

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Internal Medicine
2022
2032
   

BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Kasi PM, Kamatham S, Shahjehan F, Li Z, Johnson PW, Merchea A, Colibaseanu DT. BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer. J Gastrointest Oncol. 2020 Apr;11(2):236-241. PMCID: PMC7212105
2. Kamatham S, Shahjehan F, Kasi PM. Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer. Front Pharmacol. 2020;11:23. PMCID: PMC7025641
3. Yarlagadda B, Kamatham V, Ritter A, Shahjehan F, Kasi PM. Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma. NPJ Precis Oncol. 2019;3:19. PMCID: PMC6700112
4. Shahjehan F, Kamatham S, Ritter A, Kasi PM. Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer. Clin Case Rep. 2019 Sep;7(9):1729-1734. PMCID: PMC6745381
5. Shahjehan F, Kamatham S, Kasi PM. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018. Front Oncol. 2019;9:358. PMCID: PMC6519295
6. Merchea A, Shahjehan F, Croome KP, Cochuyt JJ, Li Z, Colibaseanu DT, Kasi PM. Colorectal Cancer Characteristics and Outcomes after Solid Organ Transplantation. J Oncol. 2019;2019:5796108. PMCID: PMC6421000
7. Wang CB, Shahjehan F, Merchea A, Li Z, Bekaii-Saab TS, Grothey A, Colibaseanu DT, Kasi PM. Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. Front Oncol. 2019;9:76. PMCID: PMC6389639
8. Kasi PM, Koep T, Schnettler E, Shahjehan F, Kamatham V, Baldeo C, Hughes CL. Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer. Technol Cancer Res Treat. 2019 Jan 01;18:1533033819873924. PMCID: PMC6753511
9. Shahjehan F, Merchea A, Cochuyt JJ, Li Z, Colibaseanu DT, Kasi PM. Body Mass Index and Long-Term Outcomes in Patients With Colorectal Cancer. Front Oncol. 2018;8:620. PMCID: PMC6315135
10. Kasi PM, Shahjehan F, Cochuyt JJ, Li Z, Colibaseanu DT, Merchea A. Rising Proportion of Young Individuals With Rectal and Colon Cancer. Clin Colorectal Cancer. 2019 Mar;18(1):e87-e95.
11. Shahjehan F, Kasi PM, Habermann E, Day CN, Colibaseanu DT, Mathis KL, Larson DW, Merchea A. Trends and outcomes of sphincter-preserving surgery for rectal cancer: a national cancer database study. Int J Colorectal Dis. 2019 Feb;34(2):239-245.
12. Kasi PM, Maige CL, Shahjehan F, Rodgers JM, Aloszka DL, Ritter A, Andrus ML, Mcmillan JM, Mody K, Sharma A, Jain MK. A Care Process Model to Deliver <sup>177</sup>Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors. Front Oncol. 2018;8:663. PMCID: PMC6333662
13. Shahjehan F, Kamatham S, Chandrasekharan C, Kasi PM. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. Drugs Today (Barc). 2019 Nov;55(11):683-693.
14. Kamatham S, Shahjehan F, Kasi PM. Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: Current Status, Recent Advances, and Future Directions. Current Colorectal Cancer Reports. 2019. https://doi.org/10.1007/s11888-019-00437-z
 
Books, Chapters, and Reviews
1. Kamatham S, Shahjehan F, Kasi PM. Metastatic Anal Cancer. Handbook of Gastrointestinal Cancers: Evidence-Based Treatment and Multidisciplinary Patient Care. 2019. https://www.springerpub.com/handbook-of-gastrointestinal-cancers-9780826138125.html.